Classical and Modern Approaches Used for Viral Hepatitis Diagnosis

authors:

avatar Mohammad Heiat 1 , avatar Reza Ranjbar ORCID 1 , * , avatar Seyed Moayed Alavian 2

Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Middle East Liver Disease Center (MELD), Tehran, IR Iran

how to cite: Heiat M, Ranjbar R, Alavian S M. Classical and Modern Approaches Used for Viral Hepatitis Diagnosis. Hepat Mon. 2014;14(4):e17632. https://doi.org/10.5812/hepatmon.17632.

Abstract

Context:

Viral hepatitis diagnosis is an important issue in the treatment procedure of this infection. Late diagnosis and delayed treatment of viral hepatitis infections can lead to irreversible liver damages and occurrence of liver cirrhosis and hepatocellular carcinoma. A variety of laboratory methods including old and new technologies are being applied to detect hepatitis viruses. Here we have tried to review, categorize, compare and illustrate the classical and modern approaches used for diagnosis of viral hepatitis.

Evidence Acquisition:

In order to achieve a comprehensive aspect in viral hepatitis detection methods, an extensive search using related keywords was done in major medical library and data were collected, categorized and summarized in different sections.

Results:

Analyzing of collected data resulted in the wrapping up the hepatitis virus detection methods in separate sections including 1) immunological methods such as enzyme immunoassay (EIA), radio-immunoassay (RIA) immuno-chromatographic assay (ICA), and immuno-chemiluminescence 2) molecular approaches including non-amplification and amplification based methods, and finally 3) advanced biosensors such as mass-sensitive, electrical, electrochemical and optical based biosensors and also new generation of detection methods.

Conclusions:

Detection procedures in the clinical laboratories possess a large diversity; each has their individual advantages and facilities' differences.

1. Context

Viral hepatitis is caused by several viruses known as hepatitis viruses. The most common types of hepatitis viruses include hepatitis A virus (HAV), B (HBC), C (HCV), D (HDV) and E (HEV). About 1.4 million people become infected by HAV around the world annually. More than 240 million people live with chronic HBV infection and about 600 thousand people die every year from acute or chronic HBV infection. About 150 million people globally have chronic HCV infection and more than 350 thousand people die every year due to HCV-related liver diseases (1). Hepatitis viruses are different in genomic type, antigenic patterns, mode of transmission, severity and chronicity, etc. (2). During recent years, some considerable efforts have been devoted toward development of various techniques to detect hepatitis virus derivative targets including: IgM and IgG for HAV, all serological markers (anti-HBc antibodies [IgM and IgG], anti-HBe antibody, HBeAg and HBsAg), and HBV DNA for HBV (3), anti-HCV antibodies and HCV RNA for HCV, anti-HDV antibodies and HDV antigen for HDV and anti-HEV antibodies and HEV RNA for HEV (4). Immunoassay methods were described as general and versatile techniques for identification of pathogenic agents (5). The most commonly and also traditionally used immunoassay techniques for detection of hepatitis viruses are RIA (6, 7) and ELISA (8). Immunochemiluminescent assay, and lateral flow immunoassay are among more advanced immunoassay techniques. Recently, molecular approaches have been converted into unavoidable implements to diagnose viral disease, with accurate and reliable results (9, 10). Widely utilized molecular methods for detection of hepatitis viruses relies on nucleic acid amplification. Signal, target and probe amplifications are described as formats of amplification based methods (11, 12). Nowadays the modern techniques for hepatitis detection are intellectual combinations between serological and molecular methods, jointed with nanotechnology, chemistry, electronics and high-tech apparatus. On the other hand, some newfound recognizer elements such as aptamers are emerging to help scientists to identify the hepatitis virus easier than past (13). In this review, it was intended to investigate the classical and modern techniques in diagnosis of hepatitis viruses and introduce the developed and advanced methods available in this field.

2. Evidence Acquisition

In this review article after determination of the main concepts and statement about the problem, attempts made to gather data about the aims and aspects, from major databases including PubMed, EMBASE and Scopus from 1970 to 2013. In this regard the most relevant keywords such as hepatitis viruses, classical and novel detection techniques, immunoassay, biosensors, molecular detection methods and many more were used to construct thesaurus in different databases. Irrespective to any classification, about 120 full articles and 50 abstracts were obtained from above mentioned databases. Thereafter different techniques and data were analyzed, categorized and compared with each other. Finally unpredictable, digressive and redundant data were discarded and the main collected points were arranged, summarized and divided into different sections.

3. Results

Resultant items and findings about classical and modern approaches used for viral hepatitis diagnosis were collected in different parts including immunological methods, molecular approaches and advanced biosensors. An analytical outline of each class of detection method presented below.

3.1. Immunoassay

Hepatitis virus derived antigens and antibodies are the main subjects for all immunoassay techniques. Antibodies as the detector elements play the central role in different formats of immunoassay methods. The most important and usual serological methods to detect hepatitis viruses include; enzyme immunoassay (EIA), radio-immunoassay (RIA) immuno-chromatographic assay (ICA), and immuno-chemiluminescence.

3.1.1. Enzyme-Linked Immunosorbent Assay

Enzyme-linked immunosorbent assay (ELISA) accounts as a high sensitive method to detect many samples during a short time. The main component of ELISA is an enzyme conjugated antibody, the activity of which, is to produce a colored production (14). ELISA can accurately determine the presence of derived antigens or raised antibodies against hepatitis viruses (15). ELISA procedure is performed in four formats (Figure 1). ELISA kits are widely used to detect hepatitis viruses in clinical laboratories. In recent years, optimized ELISA methods have been developed to detect hepatitis in more accurate and sensitive ways through changing of influencing ELISA factors. In this regard, Kuo and colleagues in 2012 designed an ELISA technique to measure anti-HDV antibody. In this method a recombinant 127 amino acid HDAg, was used as the specific target. The sensitivity and specificity of their model were 97.3 and 100% respectively in comparison with RIA (16). Ansaldi and colleagues have also evaluated a model of ELISA for simultaneous detection of anti-HCV antibody and HCV core antigen (17).

Based on the Layout Experiment and Antigen and Antibody Alignment, ELISA Can Be Classified Into Four Different Models
A. Direct ELISA; B. Indirect ELISA; C. Sandwich ELISA; D. Competitive ELISA

3.1.2. Radioimmunoassay

Radioimmunoassay (RIA) is the first generation of serological techniques and is a suitable tool to detect hepatitis viruses. In RIA a cold antigen (a non-radioactive one) competes with a hot antigen (an antigen conjugated with radioactive materials) for binding to antibodies (18). Therefore target concentration (non-conjugated target) and radiation have the inverse relation. Lander et al. are the pioneers of using modified RIA to detect hepatitis-associated antigen (HAA) followed by (19) countless studies on hepatitis viruses, performed on the basis of radioimmunoassay. Nowadays RIA is an extensively used technique to diagnose all types of hepatitis viruses in a commercial kit format.

3.1.3. Immunochemiluminescent Assay

In 1976 the chemiluminogenic (CL) reagent was used for the first time as a non-isotopic label in an immunoassay system. CL labels are categorized into consumed and non-consumed labels, both employed for detection of viral hepatitis (20). Oxidation of CL reagents is associated with a measurable light emission (21). Immunochemiluminescent assay (CA) showed an equal and even higher level of sensitivity in comparison with RIA (22). Comparative studies on EIA and CA have confirmed that CA has equivalent sensitivity but relatively higher specificity, predictive value and fewer false-positive results in viral hepatitis diagnosis procedures. The high stability after conjugation, low consumption of reagents, high sensitivity and high safety are of other CA advantages.

3.1.4. Lateral Flow Immunoassay

Lateral flow immunoassay (LFIA or LFA), due to its excellent advantages such as high sensitivity and specificity, ease of interpretation, simplicity of use and design and not requiring special instruments, has obtained extensive acceptance in clinical laboratories and being considered as a popular detection test (23). LFA works as a rapid test on the basis of fluid capillary movement through the sandwich (antigen or antibody sandwich) and commutative formats (Figure 2). LFA strip structure are composed of different overlapped layers include sample pad, conjugate pad, analytical membrane and absorbance pad. The liquid sample migrates through strip from sample pad to absorbance pad. Based on LFA format the appearing and disappearing of test lines determine the presence or absence of target in sample (24).

Tow Formats of Lateral Flow Immunoassay
A) Sandwich format (antigen Sandwich) and testing results B) Competitive format and testing results. Positive (+) test and negative (-) test.

LFA is used for rapid detection of hepatitis viruses and human immunodeficiency virus (HIV). Since the first use of LFA for detection of hepatitis viruses, many modifications were done to improve its function in order to make the sensitivity and detection limits of some novel LFA comparable to ELISA (25, 26). Nowadays several commercial LFA kits with high sensitivity levels are available for detection of hepatitis viruses.

3.2. Molecular Based Detection

When serological techniques are not definitive, molecular assays are very helpful for the detection of all viral hepatitis infections, especially hepatitis B and C (10). Some molecular based detection methods like real-time PCR are able to quantify hepatitis viruses DNA or RNA copy numbers accurately. Nucleic acids tests (NAT) are performed in three formats including: non amplified, amplified and advanced methods among which amplified based methods are the most important and applicable for hepatitis virus detection (10). The invention of polymerase chain reaction (PCR) is owed to amplified nucleic acid techniques. PCR and its related techniques have created an incredible revolution in viral hepatitis diagnostic procedures. Hear the efficient systems for hepatitis viruses' molecular detection are discussed.

3.2.1. Normal and Multiplex Polymerase Chain Reaction

PCR standing for polymerase chain reaction can be utilized as a valuable implement to diagnose pathogenic agent through amplification of nucleic acids conserve region (DNA or RNA). PCR technique provides a condition for synthesis of million copies of interest nucleic acid segment in a short time. Multiplex PCR is a PCR procedure in which two or more different DNA target segments are amplified in a single tube. Detection power of PCR is as few as one to ten copy number of target. PCR and its related techniques have been widely used to diagnose both DNA and RNA hepatitis viruses. Several studies proved that PCR can detect HBV DNA even in samples which in, all serological markers are negative except for anti-HBc (hepatitis B virus core antibody) (3). In HBV acute and chronic infection forms, HBV DNA is detectable whereas all serological tests are negative (27). Multiplex PCR provides a situation in which several genotype and sub-genotypes of HBV can be detected simultaneously in a single tube (28).

3.2.2. Nucleic Acid Sequence-Based Amplification and Transcription-Mediated Amplification

Nucleic acid sequence base amplification (NASBA) and transcription mediated amplification (TMA) are of target amplification molecular techniques (29). Both techniques are designed to amplify and detect RNA and therefore, are very suitable to detect RNA hepatitis viruses such as HCV and HAV. NASBA is an isothermal RNA amplification reaction in which the synthesis of RNA is performed at the presence of a pair of primer and three enzymes including: reverse transcriptase (RT), RNase H and T7 RNA polymerase. The first NASBA detection assay for amplification of HCV RNA was described in 1994 by Sillekens et al. (30) TMA too is based on RNA amplification using both RNA and DNA as templates. RT and RNA polymerase play the enzymatic role in TMA procedure. NASBA method is more suitable for detection of HAV and HCV-RNA. Normal NASBA shows very poor amplification capabilities for HBV-DNA (31). On the other hand, the TMA technique can directly use both RNA and DNA as template, making it suitable for detection of HBV-DNA.

3.2.3. Real-Time Polymerase Chain Reaction

Real-time PCR or quantitative PCR (qPCR) is a superior technology, able to diagnose and quantify hepatitis viruses based on nucleic acid amplification without post-PCR handling requirement (32). Nowadays several qPCR protocols are available to detect a number of clinically dangerous viruses, including hepatitis B and C viruses. Numerous advantages of real-time PCR including high sensitivity and specificity, high accuracy, broad dynamic range, capability to determine the quantity the viral load in specimens and many more have made this method the gold standard in hepatitis virus detection. Various fluorescent chemistries are used by qPCR to quantify DNA copy numbers. Fluorescent chemistries are generally divided into specific oligoprobes and non-specific compounds. For instance some dyes like SYBR green, non-specifically bind to double-stranded DNA while fluorescent resonance energy transfer (FRET) sequence-specific probes like dual hybridization probes specially bind to target sequences (33). In order to determine hepatitis genotypes and subtypes, qPCR is strongly able to characterize the genome of hepatitis viruses (34).

3.2.4. Loop-Mediated Isothermal Amplification

Loop mediated isothermal amplification (LAMP) as a novel and strong method for nucleic acids amplification is considered an inexpensive and rapid tool for detecting hepatitis viruses (35). Since 2000, that Notomi and colleagues have developed LAMP technique, it has been widely used for diagnosis and quantification of viral pathogens. LAMP is a potent instrument for DNA amplification in detection of HBV (36, 37) which can also be used for detection of RNA hepatitis viruses (HAV, HCV and HEV) in reverse transcription way (38). Low time consumption, isothermal conditions and also no need for specific instruments are of this method's advantages (39). Nowadays different LAMP models are available as commercial diagnostic kits for several types of hepatitis viruses.

3.2.5. Branched DNA

Branched DNA (bDNA) is a type of signal amplification technology, developed in early 90s for virus quantification. This method is initiated from hybridization of viral genomic materials with capture extenders and label extenders. Capture extenders are oligonucleotides designed to mediate the binding of targets to capture immobilized probes. Label extenders are designed to mediate binding of viral genome target to bDNA (40). Alkaline phosphatase conjugated oligonucleotide (AP-oligonucleotide) which is complementary to bDNA structure produces a signal by catalysis of alkaline phosphatase luminescent substrate (41) (Figure 3). The chemiluminescent emission resulting from AP reaction is monitored by a luminometer. Quantification of hepatitis viruses’ genome copy number is facilitated by bDNA assay through measuring the amplified signal.

A Scheme for bDNA Assay
A) First generation bDNA assay construction without preamplifier; B) second and third generation of bDNA assays. The preamplifier recruited in second and third generation bDNA assay increases the sensitivity of assay.

4. Conclusions

Viral hepatitis is considered a dangerous public health problem worldwide. Diagnosis and treatment are the main goals to inhibit the spread of hepatitis viruses. Exact diagnosis of hepatitis virus types and infection stage for an effective treatment need a relatively broad knowledge about viral hepatitis infections. Each detection technique has its special advantages and limitations. EIAs are the most important serological assays used for hepatitis viruses’ detection. EIAs procedures are simple and convenient to set up and having nano-gram or sensitivity to low levels of target presence, few reagents requirement, quantitative and qualitative testing and capability of being automated are some of the advantages of EIAs. On the other hand they can be time-consuming and expensive devices. Rapid detection of viral hepatitis, soon after infection, is an urgent requirement to treat and prevent infection transmission. Development of molecular methods for diagnosis of viral genomic materials has revolutionized the detection procedure in clinical laboratories. Some of these techniques have been introduced as common laboratory tests but some others such as real-time PCR are applied as gold-standard and reference settings. The major advantages of molecular methods are having higher specificity and sensitivity and larger dynamic range of action compared to other diagnostic methods like serological assays. Regarding nucleic acid tests, requiring special instruments and post handling in some molecular tests and inability to indicate the pathogen viability are the main limitations. Biosensors have been described for label free detection of hepatitis viruses. Most of biosensors are based on the combination of existing molecular and immunological techniques coupled with optical, electrochemical, mass-sensitive and electrical sensing modules. The main advantages of these detection systems are offering a quantitative test for detection in cases with about 100 copies of hepatitis virus, in addition to automation, multiplexing analysis and throughput. It seems further studies are necessary to completely uniform the methods that can be established as universal recommendations for detection of hepatitis viruses.

Acknowledgements

References

  • 1.

    World Hepatitis Day: More must be done to stop this silent killer. 2013;. Available from: http://www.who.int/campaigns/hepatitis-day/2013/en/.

  • 2.

    Nainan OV, Xia G, Vaughan G, Margolis HS. Diagnosis of hepatitis a virus infection: a molecular approach. Clin Microbiol Rev. 2006;19(1):63-79. [PubMed ID: 16418523]. https://doi.org/10.1128/cmr.19.1.63-79.2006.

  • 3.

    Tas T, Kaya S, Onal S, Kucukbayrak A. The detection of HBV DNA with polymerase chain reaction in blood donors with isolated hepatitis B core antibody. Med Glas (Zenica). 2012;9(2):227-30. [PubMed ID: 22926355].

  • 4.

    Francis J, Barrett SP, Ogilvie MM, Sutherland S. Best Practice No 175. Guidelines for virological and non-viral serological examination of specimens in routine diagnostic microbiological laboratories. J Clin Pathol. 2004;57(1):1-5. [PubMed ID: 14693826].

  • 5.

    Peruski AH, Peruski LF. Immunological methods for detection and identification of infectious disease and biological warfare agents. Clin Diagn Lab Immunol. 2003;10(4):506-13. [PubMed ID: 12853377].

  • 6.

    Yalow RS, Berson SA. Assay of plasma insulin in human subjects by immunological methods. Nature. 1959;184(Suppl 21):1648-9. [PubMed ID: 13846363].

  • 7.

    Purcell RH, Wong DC, Alter HJ, Holland PV. Microtiter solid-phase radioimmunoassay for hepatitis B antigen. Appl Microbiol. 1973;26(4):478-84. [PubMed ID: 4201649].

  • 8.

    Mathiesen LR, Feinstone SM, Wong DC, Skinhoej P, Purcell RH. Enzyme-linked immunosorbent assay for detection of hepatitis A antigen in stool and antibody to hepatitis A antigen in sera: comparison with solid-phase radioimmunoassay, immune electron microscopy, and immune adherence hemagglutination assay. J Clin Microbiol. 1978;7(2):184-93. [PubMed ID: 204663].

  • 9.

    Ebner K, Rauch M, Preuner S, Lion T. Typing of human adenoviruses in specimens from immunosuppressed patients by PCR-fragment length analysis and real-time quantitative PCR. J Clin Microbiol. 2006;44(8):2808-15. [PubMed ID: 16891496]. https://doi.org/10.1128/JCM.00048-06.

  • 10.

    Cobo F. Application of molecular diagnostic techniques for viral testing. Open Virol J. 2012;6:104-14. [PubMed ID: 23248732]. https://doi.org/10.2174/1874357901206010104.

  • 11.

    Arnold LJ, Hammond PW, Wiese WA, Nelson NC. Assay formats involving acridinium-ester-labeled DNA probes. Clin Chem. 1989;35(8):1588-94. [PubMed ID: 2667804].

  • 12.

    Ling MM, Ricks C, Lea P. Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies. Expert Rev Mol Diagn. 2007;7(1):87-98. [PubMed ID: 17187487]. https://doi.org/10.1586/14737159.7.1.87.

  • 13.

    Lee S, Kim YS, Jo M, Jin M, Lee DK, Kim S. Chip-based detection of hepatitis C virus using RNA aptamers that specifically bind to HCV core antigen. Biochem Biophys Res Commun. 2007;358(1):47-52. [PubMed ID: 17475212]. https://doi.org/10.1016/j.bbrc.2007.04.057.

  • 14.

    Crowther JR. The ELISA guidebook, vol. 149. New Jersey: Human Press Totowa; 2001.

  • 15.

    Hosseini SM, Ranjbar R, Abolghasemi H, Turkaman M. Evaluation of the Level of HBV Antibody Titer after HBV Vaccination among Children in Tehran, Iran. Hepat Mon. 2009;9(2):150-3.

  • 16.

    Kuo YB, Chao M, Lee YH, Yeh CT, Chan EC. New enzyme-linked immunosorbent assay for detection of antibodies against hepatitis delta virus using a hepatitis delta antigen derived from a Taiwanese clone and comparison to the Abbott radioimmunoassay. Clin Vaccine Immunol. 2012;19(5):817-9. [PubMed ID: 22398247]. https://doi.org/10.1128/CVI.05687-11.

  • 17.

    Ansaldi F, Bruzzone B, Testino G, Bassetti M, Gasparini R, Crovari P, et al. Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection. J Viral Hepat. 2006;13(1):5-10. [PubMed ID: 16364076]. https://doi.org/10.1111/j.1365-2893.2005.00646.x.

  • 18.

    Wu G. Assay development: fundamentals and practices. United States: John Wiley & Sons; 2010.

  • 19.

    Lander JJ, Alter HJ, Purcell RH. Frequency of antibody to hepatitis-associated antigen as measured by a new radioimmunoassay technique. J Immunol. 1971;106(5):1166-71. https://doi.org/10.1016/0003-2670(92)85043-6.

  • 20.

    Weeks I, Woodhead JS, Lucas I. Development of a chemiluminescence immunoassay for the detection of hepatitis B surface antigen. Anal Chim Acta. 1992;266(2):201-4. https://doi.org/10.1016/0003-2670(92)85043-6.

  • 21.

    Ornopia GL, Kuramoto K. Detection of anti-hepatitis C virus using chemiluminescence. J Viral Hepat. 1995;2(4):215-9. [PubMed ID: 7489350].

  • 22.

    Wu AH. A selected history and future of immunoassay development and applications in clinical chemistry. Clin Chim Acta. 2006;369(2):119-24. [PubMed ID: 16701599]. https://doi.org/10.1016/j.cca.2006.02.045.

  • 23.

    Posthuma-Trumpie GA, Korf J, van Amerongen A. Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats. A literature survey. Anal Bioanal Chem. 2009;393(2):569-82. [PubMed ID: 18696055]. https://doi.org/10.1007/s00216-008-2287-2.

  • 24.

    Wong RC, Tse HY. Lateral Flow Immunoassay. Germany: Springer; 2008.

  • 25.

    Xiang T, Jiang Z, Zheng J, Lo C, Tsou H, Ren G, et al. A novel double antibody sandwich-lateral flow immunoassay for the rapid and simple detection of hepatitis C virus. Int J Mol Med. 2012;30(5):1041-7. [PubMed ID: 22960954]. https://doi.org/10.3892/ijmm.2012.1121.

  • 26.

    Xia X, Xu Y, Zhao X, Li Q. Lateral flow immunoassay using europium chelate-loaded silica nanoparticles as labels. Clin Chem. 2009;55(1):179-82. [PubMed ID: 18974359]. https://doi.org/10.1373/clinchem.2008.114561.

  • 27.

    Gholami Parizad E, Khosravi A, Sayehmiri K, Ranjbar R. Detection of HBV DNA in cerumen and sera of hbsag negative patients with chronic hepatitis B infection. Iranian Red Crescent Med J. 2012;14(3):186-7.

  • 28.

    Chen J, Yin J, Tan X, Zhang H, Zhang H, Chen B, et al. Improved multiplex-PCR to identify hepatitis B virus genotypes A-F and subgenotypes B1, B2, C1 and C2. J Clin Virol. 2007;38(3):238-43. [PubMed ID: 17224304]. https://doi.org/10.1016/j.jcv.2006.12.007.

  • 29.

    Altunay H, Kosan E, Birinci I, Aksoy A, Kirali K, Saribas S, et al. Are isolated anti-HBc blood donors in high risk group? The detection of HBV DNA in isolated anti-HBc cases with nucleic acid amplification test (NAT) based on transcription-mediated amplification (TMA) and HBV discrimination. Transfus Apher Sci. 2010;43(3):265-8. [PubMed ID: 20934912]. https://doi.org/10.1016/j.transci.2010.09.012.

  • 30.

    Sillekens P, Kok W, Van Gemen B, Lens P, Huisman H, Cuypers T, et al. Specific detection of HCV RNA using NASBA as a diagnostic tool. Paris, France: Hepatitis C virus John Libbey Eurotext; 1994. p. 71-82.

  • 31.

    Deiman B, Jay C, Zintilini C, Vermeer S, van Strijp D, Venema F, et al. Efficient amplification with NASBA of hepatitis B virus, herpes simplex virus and methicillin resistant Staphylococcus aureus DNA. J Virol Methods. 2008;151(2):283-93. [PubMed ID: 18514336]. https://doi.org/10.1016/j.jviromet.2008.04.009.

  • 32.

    Khodakov DA, Zakharova NV, Gryadunov DA, Filatov FP, Zasedatelev AS, Mikhailovich VM. An oligonucleotide microarray for multiplex real-time PCR identification of HIV-1, HBV, and HCV. Biotechniques. 2008;44(2):241-6, 8. [PubMed ID: 18330353].

  • 33.

    Mackay IM, Arden KE, Nitsche A. Real-time PCR in virology. Nucleic Acids Res. 2002;30(6):1292-305. [PubMed ID: 11884626].

  • 34.

    Sanchez G, Populaire S, Butot S, Putallaz T, Joosten H. Detection and differentiation of human hepatitis A strains by commercial quantitative real-time RT-PCR tests. J Virol Methods. 2006;132(1-2):160-5. [PubMed ID: 16280175]. https://doi.org/10.1016/j.jviromet.2005.10.010.

  • 35.

    Li J, Song D, He W, Bao Y, Lu R, Su G, et al. Rapid detection of orf virus by loop-mediated isothermal amplification based on the DNA polymerase gene. Arch Virol. 2013;158(4):793-8. [PubMed ID: 23183830]. https://doi.org/10.1007/s00705-012-1526-1.

  • 36.

    Cai T, Lou G, Yang J, Xu D, Meng Z. Development and evaluation of real-time loop-mediated isothermal amplification for hepatitis B virus DNA quantification: a new tool for HBV management. J Clin Virol. 2008;41(4):270-6. [PubMed ID: 18296109]. https://doi.org/10.1016/j.jcv.2007.11.025.

  • 37.

    Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000;28(12):e63.

  • 38.

    Wang QQ, Zhang J, Hu JS, Chen HT, Du L, Wu LQ, et al. Rapid detection of hepatitis C virus RNA by a reverse transcription loop-mediated isothermal amplification assay. FEMS Immunol Med Microbiol. 2011;63(1):144-7. [PubMed ID: 21635570]. https://doi.org/10.1111/j.1574-695X.2011.00828.x.

  • 39.

    Yang J, Fang MX, Li J, Lou GQ, Lu HJ, Wu NP. Detection of hepatitis C virus by an improved loop-mediated isothermal amplification assay. Arch Virol. 2011;156(8):1387-96. [PubMed ID: 21562883]. https://doi.org/10.1007/s00705-011-1001-4.

  • 40.

    Nolte FS. Branched DNA signal amplification for direct quantitation of nucleic acid sequences in clinical specimens. Adv Clin Chem. 1998;33:201-35. [PubMed ID: 10086178].

  • 41.

    Tsongalis GJ. Branched DNA technology in molecular diagnostics. Am J Clin Pathol. 2006;126(3):448-53. [PubMed ID: 16880139]. https://doi.org/10.1309/90BU6KDXANFLN4RJ.

  • 42.

    Su L, Jia W, Hou C, Lei Y. Microbial biosensors: a review. Biosens Bioelectron. 2011;26(5):1788-99. [PubMed ID: 20951023]. https://doi.org/10.1016/j.bios.2010.09.005.

  • 43.

  • 44.

    Velusamy V, Arshak K, Korostynska O, Oliwa K, Adley C. An overview of foodborne pathogen detection: in the perspective of biosensors. Biotechnol Adv. 2010;28(2):232-54. [PubMed ID: 20006978]. https://doi.org/10.1016/j.biotechadv.2009.12.004.

  • 45.

    Pohanka M, Skladal P. Electrochemical biosensors--principles and applications. J Appl Biomed. 2008;6(2):57-64.

  • 46.

    Uliana CV, Riccardi CS, Tognolli JO, Yamanaka H. Optimization of an amperometric biosensor for the detection of hepatitis C virus using fractional factorial designs. J Braz Chem Soci. 2008;19(4):782-7. https://doi.org/10.1590/S0103-50532008000400024.

  • 47.

    Timurdogan E, Alaca BE, Kavakli IH, Urey H. MEMS biosensor for detection of Hepatitis A and C viruses in serum. Biosens Bioelectron. 2011;28(1):189-94. [PubMed ID: 21803562]. https://doi.org/10.1016/j.bios.2011.07.014.

  • 48.

    Scarano S, Mascini M, Turner AP, Minunni M. Surface plasmon resonance imaging for affinity-based biosensors. Biosens Bioelectron. 2010;25(5):957-66. [PubMed ID: 19765967]. https://doi.org/10.1016/j.bios.2009.08.039.

  • 49.

    Frasconi M, Tel-Vered R, Riskin M, Willner I. Surface plasmon resonance analysis of antibiotics using imprinted boronic acid-functionalized Au nanoparticle composites. Anal Chem. 2010;82(6):2512-9. [PubMed ID: 20170134]. https://doi.org/10.1021/ac902944k.

  • 50.

    Aslan K, Previte MJ, Zhang Y, Geddes CD. Microwave-accelerated surface plasmon-coupled directional luminescence 2: a platform technology for ultra fast and sensitive target DNA detection in whole blood. J Immunol Methods. 2008;331(1-2):103-13. [PubMed ID: 18230398]. https://doi.org/10.1016/j.jim.2007.12.004.

  • 51.

    Jacques C, Curie P. An oscillating quartz crystal mass detector. Rendu. 1880;91:294-7.

  • 52.

    Yao C, Zhu T, Tang J, Wu R, Chen Q, Chen M, et al. Hybridization assay of hepatitis B virus by QCM peptide nucleic acid biosensor. Biosens Bioelectron. 2008;23(6):879-85. [PubMed ID: 17951045]. https://doi.org/10.1016/j.bios.2007.09.003.

  • 53.

    Vashist SK. A review of microcantilevers for sensing applications. J Nanotech. 2007;3:1-18.

  • 54.

    Lee S, Cho J, Lee YH, Jeon S, Cha HJ, Moon W. Measurement of Hepatitis B Surface Antigen Concentrations Using a Piezoelectric Microcantilever as a Mass Sensor. J Sens. 2011;2012.

  • 55.

    Cha BH, Lee SM, Park JC, Hwang KS, Kim SK, Lee YS, et al. Detection of Hepatitis B Virus (HBV) DNA at femtomolar concentrations using a silica nanoparticle-enhanced microcantilever sensor. Biosens Bioelectron. 2009;25(1):130-5. [PubMed ID: 19616931]. https://doi.org/10.1016/j.bios.2009.06.015.

  • 56.

    Balogh Z, Lautner G, Bardoczy V, Komorowska B, Gyurcsanyi RE, Meszaros T. Selection and versatile application of virus-specific aptamers. FASEB J. 2010;24(11):4187-95. [PubMed ID: 20624933]. https://doi.org/10.1096/fj.09-144246.

  • 57.

    Hwang KS, Lee SM, Eom K, Lee JH, Lee YS, Park JH, et al. Nanomechanical microcantilever operated in vibration modes with use of RNA aptamer as receptor molecules for label-free detection of HCV helicase. Biosens Bioelectron. 2007;23(4):459-65. [PubMed ID: 17616386]. https://doi.org/10.1016/j.bios.2007.05.006.